While anti-PD-1/PD-L1 antibodies could be an option for ALK+ NSCLC patients, especially crizotinib-resistant ones, combining ALK-TKIs with anti-PD-1/PD-L1 antibodies requires further study before clinical use [114]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.